Year: 2024
Type: editorial
Abstract: Adenoid cystic carcinoma (ACC) is a rare malignancy of secretory glands with dual biological and clinical behavior.Although most patients initially present with locally advanced disease, 50-60% of cases experience distant metastasis, for which there are limited therapeutic options [1].Our team has previously reported two major molecular ACC subtypes based on proteogenomic and clinical data [2].ACC-I, the most aggressive type of ACC, is characterized by solid histology, NOTCH1 mutation enrichment, early development of metastasis including to visceral organs and poor prognosis (median overall survival (mOS) = 3.4 ys).While ACC-II is more prevalent (66% of the cases) and characterized by nonsolid histology (cribriform and/or tubular), upregulation of p63 and receptor tyrosine kinases, predominantly lung metastasis and an overall indolent course (mOS = 23 ys).These differences underscore the intrinsic heterogeneity of ACC and the need for personalized therapies to improve clinical outcomes of patients facing this disease.
Source: Oncotarget
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Award: G4119534169
OpenAlex ID: W4404634040